Related by context. All words. (Click for frequent words.) 69 P = .# 68 n = 68 â ‰ ¥ 67 p = #.# [002] 66 % CI #.#-#.# [006] 66 ‰ ¥ 66 p = #.# [004] 65 LVEF 65 % CI #.#-#.# [007] 65 % CI #.#-#.# [003] 65 % CI #.#-#.# [002] 64 mcg BID 64 REYATAZ r arm 64 lopinavir r arm 63 laboratory abnormalities 63 macroalbuminuria 63 aged ≥ 63 MADRS score 63 postoperatively 63 alanine aminotransferase 63 μmol L 63 p = .# [002] 63 mg BID 63 % Confidence Interval 63 leukopenia 62 p = 62 lymphopenia 62 aspartate aminotransferase 62 evaluable 62 ± 62 posttreatment 62 ≤ 62 DLTs 62 aspartate aminotransferase AST 62 dyspnea 62 mL kg 62 univariate analysis 62 leucopenia 62 -#.# ± [002] 61 HBeAg seroconversion 61 Psoriasis Area 61 confidence interval CI 61 mg ustekinumab 61 preoperative PSA 61 highest tertile 61 ALT elevations 61 biochemical relapse 61 achieved ACR# 61 IPSS 61 hypophosphatemia 61 alanine aminotransferase ALT 61 nonfatal MI 61 lowest tertile 61 euthyroid 60 confidence interval #.#-#.# 60 p = NS 60 oxycodone CR 60 clinically meaningful improvement 60 CR nPR 60 elevated ALT 60 TEAEs 60 febrile neutropenia 60 tertiles 60 serum ALT 60 hours postdose 60 x ULN 60 ng mL 60 erythrocyte sedimentation rate 60 thrombocytopenia 60 #mg QD [002] 60 nondiabetic patients 60 QTcF 60 mCi 60 IU ml 60 hematologic toxicity 60 severe neutropenia 60 mg TID 60 Index CDAI 60 NIH CPSI 60 % CI #.#-#.# [008] 59 binary restenosis 59 ± SD 59 #mg/m# [001] 59 PaO 2 59 definite stent thrombosis 59 LV ejection fraction 59 PSA nadir 59 undetectable HBV DNA 59 8mg/kg 59 Secondary endpoints included 59 microg 59 4mg/kg 59 μg kg 59 PREZISTA r arm 59 ipsilateral stroke 59 DAS# [002] 59 μg mL 59 NYHA class 59 MBq 59 interquartile range 59 CCyR 59 MetS 59 generalized edema 59 transaminase elevations 59 mg QD 59 sd = 59 #mg BID [001] 59 CI -#.# 59 nonobese 59 CR CRu 59 serum IGF 59 histologically confirmed 59 ALT flares 58 mU L 58 CI #.#-#.# [001] 58 mg/m2 dose 58 atazanavir ritonavir 58 mL/min/#.# m2 58 elevated LDH 58 mg kg dose 58 EDSS score 58 ug kg 58 creatinine ratio 58 timepoint 58 ug dose 58 SCr 58 Primary endpoints 58 advanced adenoma 58 biochemical recurrence 58 mcg QD 58 HbA 1c 58 μg 58 ng dL 58 tertile 58 Secondary endpoints include 58 ertapenem 58 overt nephropathy 58 ml kg 58 estimated glomerular filtration 58 CI #.#-#.# [002] 58 detrusor 58 hypokalemia 58 treatment emergent adverse 58 microalbuminuria 58 #mg/kg [002] 58 colorectal adenoma 58 adjunctive placebo 58 hematuria 58 hip BMD 58 mIU L 58 Secondary endpoints 58 leukocyte count 58 fatigue asthenia 58 postop 58 mcg kg 58 timepoints 58 Brief Psychiatric 58 sensory neuropathy 58 mg/m2/day 58 posttransplant 58 mg m² 58 % CI #.#-#.# [004] 58 μg d 58 acneform rash 58 NYHA functional class 58 anemia hemoglobin 58 Partial Responses 58 preoperatively 58 neutropaenia 58 confidence intervals CIs 58 QTc 57 mL/min/#.# m 2 57 median PFS 57 RECIST criteria 57 plus methotrexate 57 QRS duration 57 serum testosterone 57 -#.# ± [001] 57 HBeAg 57 WOMAC pain 57 NNT = 57 HBeAg positive patients 57 spine BMD 57 ACR Pedi 57 alkaline phosphatase 57 endometrial thickness 57 DAS# CRP 57 arterial thromboembolic events 57 BMI ≥ 57 transaminases 57 GERD symptom 57 mEq L 57 cytopenias 57 subscore 57 HOMA IR 57 systolic BP 57 sUA 57 CI = 57 pT3 57 QD dosing 57 mg/# hours 57 nmol 57 HbA 1c levels 57 left ventricular LV 57 coronary stenosis 57 Exclusion criteria 57 NIHSS 57 events AEs 57 International Prostate Symptom 57 hemodynamically significant 57 ALT elevation 57 HIV RNA 57 certolizumab 57 abdominal circumference 57 aminotransferase elevations greater 57 g dl 57 vitreous haze 57 virologic response 57 receiving VICTRELIS 57 dyspareunia 57 pmol L 57 #μg [002] 57 neutropenia febrile neutropenia 57 hypocalcemia 57 mg/m2 57 serum aminotransferase levels 57 ULN 57 partial remissions 57 Visual Analogue Scale VAS 56 baseline FEV 56 pericardial effusions 56 dysuria 56 Hemoglobin A1c HbA1c 56 femoral neck BMD 56 SGPT 56 ventricular dilatation 56 LEXIVA r 56 pleural effusion 56 umol L 56 de novo AML 56 paresthesias 56 LPV r 56 #.#ng/ml 56 EDSS scores 56 biopsy Gleason 56 progression TTP 56 serum magnesium 56 creatinine clearance 56 glycated hemoglobin levels 56 IU mL 56 #mg BID [003] 56 kg m² 56 AST ALT 56 = #.#-#.# 56 advanced neoplasia 56 Crohn Disease Activity 56 left ventricular systolic 56 liver histology 56 postintervention 56 COPD exacerbation 56 composite endpoint 56 MACCE 56 nodular 56 thromboembolic 56 lumbar spine BMD 56 mild renal impairment 56 neutrophil count 56 aminotransferases 56 log# copies mL 56 CK MB 56 patients evaluable 56 hypomagnesemia 56 FluCAM arm 56 baseline HbA1c 56 p = .# [001] 56 mg qd 56 mcg mL 56 CC genotype 56 postvaccination 56 kg/m2 56 mL sec 56 nmol l 56 ACR# response 56 mg d 56 antibody titer 56 achieved statistical significance 56 evaluable subjects 56 placebo p = 56 serum cortisol 56 subscales 56 serum potassium 56 apnea hypopnea index 56 Dose limiting toxicities 56 serum concentrations 56 nonsignificant 56 Postoperative 56 neutropenia dehydration dyspnea 56 -#.# log# 56 % CI #.#-#.# [005] 56 mU liter 56 HGPIN 56 ejection fractions 56 peripheral sensory neuropathy 56 placebo 56 Hb A1C 56 onset diabetes mellitus 56 #Gy 56 SGRQ 56 Flu Cy 56 crossclamp 56 vertebral fracture 56 urinary albumin 56 thromboembolic events 56 hsCRP levels 56 FOLPI 56 -#.# mg dL [002] 56 #μg [001] 56 normotensive 56 CDAI score 56 SBP DBP 56 Expanded Disability Status 56 hyperintensities 56 uM 56 RBC transfusion 56 pericardial effusion 56 BMI z 56 cerebrovascular events 56 β blockers 56 serum prostate 56 mmol l 56 subtrochanteric 56 IIIa inhibitors 56 mg kg 55 ng ml 55 CRp 55 multivariable analysis 55 CrCl 55 Unified Parkinson Disease 55 lymphocytosis 55 virologic breakthrough 55 AUCs 55 UPDRS 55 histologic 55 CSBM 55 ml min 55 ug mL 55 nasopharyngitis 55 aortic regurgitation 55 histologically 55 hemoglobin Hb 55 mg/# h 55 specific antigen PSA 55 hemoptysis 55 ECOG PS 55 rheumatoid factor 55 serum HCV RNA 55 severe exacerbations 55 nmol L 55 fasting insulin 55 p = #.# [003] 55 intima media thickness 55 normal ULN 55 TT genotype 55 serum HBV DNA 55 abdominal pain abdominal discomfort 55 invasive carcinomas 55 lumbar spine bone 55 subscores 55 pg mL 55 min -1 55 underwent resection 55 lispro 55 HBeAg negative patients 55 subclinical hypothyroidism 55 #ug [001] 55 milliliters mL 55 Partial Response 55 nodular partial response 55 elevated transaminases 55 ALT normalization 55 Thrombolysis 55 spinal cord compression 55 intact parathyroid hormone 55 EBRT 55 virologic failure 55 receiving golimumab 55 copies mL 55 dapagliflozin plus 55 mucosal inflammation 55 plasma uric acid 55 CDAI 55 plasma leptin 55 hypogonadal 55 atrioventricular block 55 #mg/day [001] 55 Severity Index PASI 55 pyrexia 55 Asymptomatic 55 Median PFS 55 Montgomery Åsberg Depression 55 urinary N telopeptide 55 NSTEMI 55 intravitreal injections 55 Scale EDSS score 55 Tumor shrinkage 55 nM 55 mcg albinterferon alfa 2b 55 isoprostane 55 adjunctive ABILIFY 55 nonvertebral fractures 55 primary aldosteronism 55 postprocedure 55 URTI 55 Serum creatinine 55 tipranavir r 55 incidence ≥ 55 peripheral edema 55 placebo p 55 fasting plasma glucose 55 mRS 55 hematologic adverse 55 CIN2 + 55 undetectable HCV RNA 55 #mg/m# [002] 55 urine albumin 55 serum phosphorus 55 mg BID dose 55 diameter stenosis 55 subscale scores 55 PSQI 55 X ULN 55 Cmax 55 receiving ISENTRESS 55 APACHE II 55 stomatitis 55 Hazard Ratio HR 55 μg L 55 eGFR 55 Disease Activity 55 diastolic hypertension 55 μg liter 55 Median survival 55 normothermic 55 histologic subtype 55 aminotransferase levels 55 mol L 55 6MWD 55 mmol 55 adefovir treated 55 serum ferritin 55 PASI scores 55 HSCT 55 femoral neck 55 thrombocytopenic 55 mCi m 2 55 microgram kg 55 rCBF 55 recurrent ischemia 55 alanine transaminase 55 inflammatory lesions 55 detrusor overactivity 55 evaluable patients 55 histologically proven 54 Kaplan Meier analysis 54 proteinuria 54 sinus rhythm 54 creatine phosphokinase 54 kg -1 54 fasting triglyceride levels 54 mg dL 54 Fasting plasma glucose 54 p ≤ 54 glycosylated hemoglobin 54 cytogenetic response 54 hypoglycemic events 54 IRLS 54 seronegative 54 mmHg diastolic 54 Q2W 54 plasma cortisol 54 FEV ^ sub 54 Adverse events 54 left ventricular dysfunction 54 serum creatinine 54 aminotransferase ALT 54 carotid artery intima media 54 baseline serum creatinine 54 recurrent VTE 54 adenoma 54 urinary sodium excretion 54 methotrexate monotherapy 54 MCyR 54 octreotide LAR 54 Â ± 54 Multivariate analysis showed 54 multivariate adjustment 54 HCV genotype 54 DAS# remission 54 oral glucose tolerance 54 hypercalciuria 54 elevated IOP 54 aplastic anemia AA 54 complete cytogenetic 54 mild renal insufficiency 54 alanine transaminase ALT 54 liver transaminases 54 preoperative 54 Target Lesion Revascularization TLR 54 HAM D# scores 54 PREZISTA ritonavir 54 atheroma volume 54 systolic dysfunction 54 systemic corticosteroid 54 distant metastases 54 statistically significant p 54 IBDQ 54 preintervention 54 hepatic enzymes 54 intramuscularly 54 epistaxis 54 pruritis 54 achieved PASI 54 5-FU/LV 54 relapsed MM 54 mesalamine granules 54 moderate renal impairment 54 lopinavir r 54 stent binary restenosis 54 Kruskal Wallis test 54 cerebrovascular accident 54 HDRS 54 PSADT 54 #mm Hg 54 cytogenetic responses 54 prespecified secondary 54 pT2 54 CTEPH 54 NPH insulin 54 depressive symptomatology 54 TMC# r 54 elevated troponin 54 mL min 54 log# 54 mmHg systolic 54 postdose 54 OGTT 54 CsA 54 seminal vesicle invasion 54 desvenlafaxine succinate 54 T1a 54 piperacillin tazobactam 54 μg ml 54 CSBMs 54 nonresponders 54 Left Ventricular Ejection Fraction 54 amoxicillin clavulanate 54 #mg/day [002] 54 mg 54 HBeAg positive 54 MMSE score 54 Pearson correlation coefficient 54 mm Hg diastolic 54 remission CR 54 CIN3 54 detectable HCV RNA 54 postoperative complication 54 PCa 54 mcg linaclotide 54 Rating Scale MADRS 54 ropivacaine 54 transaminase 54 neutrophil counts 54 nondiabetic 54 IRLS score 54 tapentadol ER 54 AUC0 54 Scale EDSS 54 ß blockers 54 #.#-#.# [011] 54 elevated creatinine 54 arterial oxygen saturation 54 Baseline characteristics 54 prospectively defined 54 headache nasopharyngitis 54 nonfatal myocardial infarction 54 non splenectomized 54 saline placebo 54 diastolic BP 54 renal insufficiency 54 #ng/ml 54 osteopenic 54 treatment emergent AEs 54 cTnI 54 apnea hypopnea 54 IQR 54 univariate analyzes 54 proctitis 54 pegylated interferon alfa 2b 54 pimecrolimus cream 54 events TEAEs 54 oxygen desaturation 54 pathologic fracture 54 gastroduodenal 54 UPDRS motor 54 #.#g/day 54 ribavirin RBV 54 endophthalmitis 54 hyperintensity 54 adverse reactions incidence 54 renal impairment 54 serum creatinine levels 54 hydronephrosis 54 morphometric vertebral fractures 54 Ejection Fraction 54 unresectable HCC 54 HbA1c levels 54 multivariable adjusted 54 P ≤ 54 hematologic toxicities 54 serum phosphate levels 54 pretransplant 54 #mg QD [001] 53 chest radiography 53 QIDS SR 53 % CI #.#-#.# [001] 53 primary efficacy endpoint 53 serum leptin 53 gm dL 53 GH deficiency 53 intravenous bolus 53 nontraumatic 53 #.#mg/dL 53 nasal symptom 53 cTnT 53 serum PSA 53 mmol L 53 incontinence episodes 53 clinically meaningful improvements 53 haematologic 53 pCR 53 metformin monotherapy 53 VLBW 53 peak VO2 53 mIU ml 53 postoperative AF 53 thromboembolic complications 53 pmol 53 TURBT 53 autonomic dysfunction 53 hematological adverse 53 serum triglycerides 53 μg dL 53 postmenopausal osteoporotic women 53 PsA 53 lamivudine monotherapy 53 WOMAC scores 53 g dL 53 YMRS 53 bortezomib refractory 53 Multivariate analysis 53 superficial edema 53 serum urate 53 HAMD 53 lymph node metastasis 53 Insulin sensitivity 53 NNRTI resistance 53 CIMZIA TM certolizumab pegol 53 urinary albumin excretion 53 recurrent venous thromboembolism 53 Febrile neutropenia 53 coronary calcification 53 homozygotes 53 abacavir lamivudine 53 LV dysfunction 53 diabetes mellitus DM 53 ADAS cog 53 interquartile range IQR 53 resected 53 atherogenic dyslipidemia 53 symptomatic VTE 53 Postoperative complications 53 salmeterol fluticasone propionate 53 Apgar scores 53 conjunctival hyperemia 53 achieving PASI 53 chlorambucil 53 recurrent UTI 53 PANSS 53 ACR# responses 53 extensive metabolizers 53 graft dysfunction 53 Operative mortality 53 advanced adenomas 53 parenchymal 53 fluorouracil leucovorin 53 ABC/3TC 53 hypercalcemia 53 graft occlusion 53 ACR# ACR# 53 sinus node dysfunction 53 femoral shaft fracture 53 affective psychosis 53 PANSS total 53 VT VF 53 HF hospitalization 53 intratumoral 53 unstable angina pectoris 53 arthralgias 53 insulin detemir 53 #mg BID [002] 53 intraobserver 53 Histologic 53 ipsilateral 53 Main Outcome Measures 53 logistic regression model 53 carotid intima media 53 CIMZIA TM 53 serum PTH 53 NIHSS score 53 periventricular 53 CK # plasma concentrations 53 radiotherapy RT 53 Acetate Rectal Suppositories 53 seropositivity 53 #q# deletion syndrome 53 FDG uptake 53 log# reduction 53 symptom onset 53 secondary endpoint 53 Zometa hazard 53 dosed intravenously 53 #OHD 53 cGy 53 NMIBC 53 oral allopurinol 53 prospectively randomized 53 -5 -6 53 creatine kinase MB 53 odds ratios ORs 53 pyrexia mucositis sepsis febrile 53 undetectable viral load 53 HIV uninfected 53 fasting plasma glucose FPG 53 dermatologic toxicities 53 plasminogen activator inhibitor 53 antiretroviral naïve 53 histological subtype 53 serum bilirubin 53 proximal DVT 53 receiving highly emetogenic 53 nadroparin 53 HbA1C levels 53 5FU 53 neoplasm 53 SUVmax 53 plasma glucose 53 HBV DNA 53 idiopathic PAH 53 renal allograft 53 hepatic enzyme 53 TRAS 53 ìg 53 plus MTX 53 rizatriptan 53 creatine kinase 53 TP# mutations 53 complete cytogenetic response 53 Incontinence Impact Questionnaire 53 plus ribavirin 53 Postoperatively 53 mediastinal 53 serum uric acid 53 serum phosphate 53 triiodothyronine 53 MADRS 53 uL 53 Ishak fibrosis score 53 TIMP 53 vesicoureteral reflux 53 tolterodine ER 53 HBsAg 53 serum transaminases 53 GnRH agonist 53 discontinuations due 53 MIC# [001] 53 albuminuria 53 severe NCI CTC 53 mm Hg systolic 53 secondary efficacy endpoint 53 sonographically 53 ATACAND 53 comorbidities 53 systolic function 53 periprocedural 53 radiographically 53 q#h 53 intraocular inflammation 53 conduction velocity 53 lactate dehydrogenase 53 polyposis 53 abdominal distension 53 concomitant antibiotics 53 serum albumin 53 ATV RTV 53 BENICAR HCT 53 DAS# scores 53 peginterferon alfa 2b 53 #mmHg [001] 53 bronchoalveolar lavage BAL 53 median survivals 53 statistically significant 53 intra articular injection 53 microbiologically evaluable 53 glycosylated hemoglobin HbA1c 53 Secondary efficacy endpoints 53 ADAS Cog 53 mcg 53 mg dose 53 nonsignificant difference 53 lactate dehydrogenase LDH 53 intramuscular dose 53 logistic regression analysis 53 #mg/dl 53 symptomatic GERD 53 pg ml 53 extracapsular extension 53 serum parathyroid hormone 53 PEG IFN 53 renal function 53 CHOP chemotherapy 53 TAXUS p value 53 bosentan 53 gastrointestinal perforation 53 thyroid carcinoma 53 glomerular filtration 53 tHcy 53 nonoperative treatment 53 asymptomatic 53 fasting plasma 53 EDSS 53 tricuspid 53 transferrin saturation 53 neurologic progression 53 postinjury 53 ug ml 52 adalimumab 52 tumor progression TTP 52 telopeptide 52 ischemia driven 52 abdominal pain flatulence 52 Hazard Ratio = 52 LS BMD 52 headache abdominal pain 52 NATRECOR ® 52 peginterferon alfa 2a #KD 52 intraperitoneally 52 rFSH 52 statistically significant reduction 52 nonvertebral 52 BMI waist circumference 52 total thyroidectomy 52 FEV1 52 tibiofemoral 52 chest radiograph 52 #ug [002] 52 del 5q MDS 52 CVD mortality 52 comparator arm 52 r = 52 myocardial infarction stroke 52 NYHA 52 stage IIIB 52 #.#mmol L [002] 52 serum CRP 52 univariate 52 dyspnoea 52 urate lowering therapy 52 nmol liter 52 erythema 52 flutamide 52 SELENA SLEDAI 52 tPSA 52 BRCA1 mutation carriers 52 tricuspid regurgitation 52 lamivudine refractory patients 52 perioperative mortality 52 lymphocyte count 52 gadolinium enhancing 52 Pred Forte 52 virologic response EVR 52 nausea photophobia 52 cervical intraepithelial neoplasia 52 Kellgren Lawrence 52 fractional shortening 52 β = 52 biventricular repair 52 postoperative hemorrhage 52 asthenia 52 pulmonary exacerbation 52 gout flares 52 albumin excretion 52 induration 52 cm2 52 HBeAg negative 52 oral antidiabetic medication 52 #m Tc 52 papillary thyroid carcinoma 52 dehydroepiandrosterone sulfate 52 radial artery grafts 52 postoperative 52 Kaplan Meier estimates 52 pulmonary artery pressure 52 FOLFIRI alone 52 retrograde ejaculation 52 aminotransferase 52 TIMI 52 hypogonadal men 52 Solid Tumors criteria 52 spontaneous bacterial peritonitis 52 hemoglobin A1c HbA1c 52 plasma folate 52 seroconversion 52 intracranial hemorrhage ICH 52 GOUT 52 urolithiasis 52 certolizumab pegol 52 ß = 52 TRAIL R1 52 trough FEV1 52 fraction LVEF 52 grade squamous intraepithelial 52 symptom severity 52 myocardial infarction MI 52 hemoglobin A1c levels 52 distant metastasis 52 PRADAXA #mg 52 glucose tolerance test 52 SVR# 52 multivariate analysis 52 HRQoL 52 #.#mg/kg [002] 52 ALT AST 52 corrected QT interval 52 transdermal estradiol 52 umbilical artery 52 mm Hg 52 ascites 52 DMARD 52 highest quintile 52 covariate 52 Y BOCS 52 RAEB 52 prevalent vertebral fracture 52 pheochromocytoma 52 intraabdominal 52 statistically significant improvement 52 serum sodium 52 radical prostatectomy RP 52 seroprotection 52 pruritus 52 distensibility 52 serologically active patients 52 events MACE 52 acromegalic patients 52 sUA levels 52 lacunar 52 caspofungin 52 surgically resected 52 Hb 52 echocardiographic 52 elevated serum creatinine 52 #mg/dL [002] 52 Univariate analysis 52 budesonide pMDI 52 splenectomized 52 Preoperatively 52 renal dysfunction 52 point Likert scale 52 androgen deprivation 52 infliximab monotherapy 52 mg kg IV 52 coinfected 52 hemoglobin concentrations 52 reinfarction 52 intraventricular hemorrhage 52 cytogenetic abnormalities 52 angiographically 52 nodal metastases 52 mg m 52 HRCT 52 arteriolar 52 mL 52 concomitant medications 52 causality incidence 52 ^ Tc 52 antibody titers 52 BENICAR 52 endoscopic remission 52 colorectal neoplasms